Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
184 hedge funds and large institutions have $2.04B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 72 increasing their positions, 59 reducing their positions, and 43 closing their positions.
509% more call options, than puts
Call options by funds: $178M | Put options by funds: $29.3M
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
22% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 59
2% more capital invested
Capital invested by funds: $2.01B → $2.04B (+$35M)
7% less funds holding
Funds holding: 197 → 184 (-13)
26% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CII
Capital International Inc
Los Angeles,
California
|
+$45.8M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$41.6M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$34.3M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$21.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$15.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$14.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$12.7M |
| 4 |
TAL
TIG Advisors LLC
New York
|
-$12.6M |
| 5 |
LM
Luminus Management
Houston,
Texas
|
-$12.6M |
BHVN Hedge Fund Activity: Q3 2019 in Review
184 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2019, worth a combined $2.04B — up 1.7% from $2.01B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of BHVN and 32 opened new positions — a net loss of 11 holders — while 59 trimmed existing stakes and 72 added.
The largest buyer was Capital International Inc, adding an estimated $45.8M. The largest seller was Great Point Partners, exiting entirely with an estimated $15.3M sold.
- 184 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2019, down from 197 in Q2 2019.
- Funds reported $2.04B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2019, up 1.7% quarter-over-quarter.
- 32 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2019 and 43 closed out, a net change of -11 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2019 was Capital International Inc, an estimated $45.8M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2019 was Great Point Partners, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2019.